Erscheint 6 Ausgaben pro Jahr
ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472
Indexed in
Quantitating Therapeutically Relevant T-Cell Responses to Cancer Vaccines
ABSTRAKT
Successful application of active immunotherapy to the treatment of cancer will require stimulation of potent antigen-specific T-cell responses. It is not known how numerous or how potent these T cells must be in order to abrogate tumors, but the levels of immunity needed to control chronic viral infections may provide estimates for comparison. Evaluation of the efficacy of a vaccine strategy in attaining these levels of immunity will depend on the use of assays that create a picture of T-cell number and function that correlates with clinical outcomes. We discuss the currently available in vivo and in vitro T-cell assays and their relevance for detecting therapeutic levels of T-cell activity. We also propose a strategy for efficiently evaluating the immunologic efficacy of cancer vaccines so that the most promising candidates can be brought more rapidly into definitive clinical trials.
-
Arlen Philip M, Wood Lauren V, Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge™ era, Expert Review of Vaccines, 11, 3, 2012. Crossref
-
Winikoff Stephen E., Zeh Herbert J., DeMarco Richard, Lotze Michael T., Cytolytic Assays, in Measuring Immunity, 2005. Crossref
-
Doehn Christian, Böhmer Torsten, Kausch Ingo, Sommerauer Martin, Jocham Dieter, Prostate Cancer Vaccines, BioDrugs, 22, 2, 2008. Crossref
-
Balint Joseph P., Gabitzsch Elizabeth S., Rice Adrian, Latchman Yvette, Xu Younong, Messerschmidt Gerald L., Chaudhry Arvind, Morse Michael A., Jones Frank R., Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer, Cancer Immunology, Immunotherapy, 64, 8, 2015. Crossref
-
Arlen Philip M., Dahut William L., Gulley James L., Immunotherapy for Prostate Cancer: What's the Future?, Hematology/Oncology Clinics of North America, 20, 4, 2006. Crossref
-
Jones Frank R., Gabitzsch Elizabeth S., Xu Younong, Balint Joseph P., Borisevich Viktoriya, Smith Jennifer, Smith Jeanon, Peng Bi-Hung, Walker Aida, Salazar Magda, Paessler Slobodan, Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine, Vaccine, 29, 40, 2011. Crossref
-
Schlom Jeffery, Gulley James L., Hodge James W., Vaccines and Immunostimulants, in Holland-Frei Cancer Medicine, 2017. Crossref
-
Newell Evan W., Lin Wenyu, High-Dimensional Analysis of Human CD8+ T Cell Phenotype, Function, and Antigen Specificity, in High-Dimensional Single Cell Analysis, 377, 2013. Crossref
-
Arlen Philip M, Gulley James L, Therapeutic Vaccines for Colorectal Cancer, American Journal of Cancer, 3, 5, 2004. Crossref
-
Arlen Philip M, Mohebtash Mahsa, Madan Ravi A, Gulley James L, Promising novel immunotherapies and combinations for prostate cancer, Future Oncology, 5, 2, 2009. Crossref
-
Alburquerque-González Begoña, López-Abellán María Dolores, Luengo-Gil Ginés, Montoro-García Silvia, Conesa-Zamora Pablo, Design of Personalized Neoantigen RNA Vaccines Against Cancer Based on Next-Generation Sequencing Data, in Pharmacogenomics in Drug Discovery and Development, 2547, 2022. Crossref
-
Caldwell Sheila A., Ryan Mary H., McDuffie Elwood, Abrams Scott I., The Fas/Fas Ligand Pathway Is Important for Optimal Tumor Regression in a Mouse Model of CTL Adoptive Immunotherapy of Experimental CMS4 Lung Metastases, The Journal of Immunology, 171, 5, 2003. Crossref